Supernus Pharma (SUPN) Tops Q3 EPS by 17c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.40, $0.17 better than the analyst estimate of $0.23. Revenue for the quarter came in at $148.5 million versus the consensus estimate of $142.12 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
• OceanaGold to acquire Ausgold in a deal valued at A$776M